| scholarly article | Q13442814 |
| P50 | author | Luca Gianni | Q56629673 |
| Massimo Broggini | Q58377329 | ||
| P2093 | author name string | C Sessa | |
| A Fasolo | |||
| P2860 | cites work | Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 |
| Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197 | Q24608143 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence | Q27851725 | ||
| A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo | Q28270305 | ||
| MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival | Q28282398 | ||
| Development of c-MET pathway inhibitors | Q34198905 | ||
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. | Q34307548 | ||
| Drug development of MET inhibitors: targeting oncogene addiction and expedience | Q34782774 | ||
| Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. | Q35203637 | ||
| The MET receptor tyrosine kinase in invasion and metastasis | Q36868644 | ||
| Targeting the MET oncogene in cancer and metastases. | Q37792116 | ||
| MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 | ||
| Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. | Q38409218 | ||
| Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth | Q39472261 | ||
| Ron kinase transphosphorylation sustains MET oncogene addiction | Q39611289 | ||
| ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. | Q39702478 | ||
| AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts | Q40050768 | ||
| MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations | Q42731321 | ||
| A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. | Q43062314 | ||
| A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors | Q43091672 | ||
| Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor | Q46121750 | ||
| Targeting the HGF/c-Met axis: state of play. | Q54676546 | ||
| P433 | issue | 1 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 14-20 | |
| P577 | publication date | 2012-10-30 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist | |
| P478 | volume | 24 |
| Q27302940 | Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model |
| Q90119555 | Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells |
| Q38940200 | Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer |
| Q36574080 | Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer |
| Q38199128 | Recent advances and future trends in the targeted therapy of metastatic gastric cancer |
| Q48140297 | Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma |
| Q89967621 | The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma |
| Q38956071 | Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines |
Search more.